Advertisement

Topics

Latest "Alnara Pharmaceuticals" News Stories

05:34 EST 22nd November 2018 | BioPortfolio

Here are the most relevant search results for "Alnara Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Alnara Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alnara Pharmaceuticals for you to read. Along with our medical data and news we also list Alnara Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alnara Pharmaceuticals Companies for you to search.

Showing "Alnara Pharmaceuticals" News Articles 1–25 of 11,000+

Probably Relevant

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma appeared first on Drug Development Technology.


GW Pharmaceuticals plc: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescr...

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Neuren Pharmaceuticals (ASX:NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Neuren retains rights to develop and commercialize trofinetide for all indications outside of North America. As quoted in the press releas...


Nuvo Pharmaceuticals to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals

NewsUpon closing of the Proposed Transaction, Nuvo would pay Aralez $110 million in cash,

Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space

Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.

Deals this week: Amicus Therapeutics, Janssen Pharmaceuticals, Ionis Pharmaceuticals

Amicus Therapeutics has entered a collaboration with the Perelman School of Medicine at the University of Pennsylvania to develop new...Read More... The post Deals this week: Amicus Therapeutics, Janssen Pharmaceuticals, Ionis Pharmaceuticals appeared first on Pharmaceutical Technology.

20182023 UK BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR DoubleCrane...

Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)

WESTON, Fla., Aug. 27, 2018 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer, today announced that the U.S. Food and Drug Administration...

Nuvo Pharmaceuticals Intends To Acquire Commercial Products And Infrastructure From Aralez Pharmaceuticals

NewsUnder the terms of the Proposed Transaction, Nuvo would acquire Aralez's Canadian specialty pharmaceutical business.

Parnell Pharmaceuticals Holdings Ltd.: Parnell Pharmaceuticals Holdings Completes Debt Refinancing With Marathon Asset Management

SYDNEY, AUSTRALIA / ACCESSWIRE / July 31, 2018 / Parnell Pharmaceuticals Holdings Ltd. (OTC PINK: PARNF) ("Parnell" or the "Company"), a fully integrated pharmaceutical company focused on developin...

20182023 Philippines BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Philippines market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare...

20182023 Malaysia BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in Malaysia, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Malaysia market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR...

20182023 India BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR Doubl...

20182023 China BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in China, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In China market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR Doubl...

Surface Pharmaceuticals secures $20m funding from Flying L Partners

Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.

Emerald Health Pharmaceuticals Inc.: Emerald Health Pharmaceuticals Announces Scientific Innovation Award Received at International Cannabis Research Society Conference

SAN DIEGO, CA / ACCESSWIRE / August 21, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced that Carmen Navarrete, Ph.D., ...

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M. E.T.  ...

Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA

NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products in the United States with the option to add products in the future.  Through the agreement, Glenmark will sell and distribute the products and Elite...

Idera Pharmaceuticals Announces Termination of Merger Agreement with BioCryst Pharmaceuticals

EXTON, Pa., July 10, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated.  The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioC...

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 8:30 A.M. E.T.  ...

Sedor Pharmaceuticals and Los Altos Pharmaceuticals sign license agreement for People’s Republic of China

PAOLI, Pa. and LOS ALTOS HILLS, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Sedor Pharmaceuticals, LLC (Sedor) and Los Altos Pharmaceuticals, Inc. (Los Altos) announce that Sedor has granted Los Altos an exclusive license for Captisol-enabled™ (CE) Meloxicam for the People’s Republic of China (PRC). Los Altos, located in Los Altos Hills, CA, has received exclusive development, manufacturing an...

COSMO Pharmaceuticals N.V.: Cosmo Pharmaceuticals' Aktion ä re stimmen; an der Generalversammlung allen Traktanden zu

Cosmo Pharmaceuticals' Aktionäre stimmenan der Generalversammlung allen Traktanden zu Amsterdam - 30. Mai 2018 - Die Aktionäre von Cosmo Pharmaceuticals N.V. (SIX: COPN) haben an der Generalversam...

Acurox Application, PTV News: May 04, 2010

King Pharmaceuticals and Acura Pharmaceuticals to seek approval of "abuse deterrent" drug

In The Spotlight: Ra Pharmaceuticals

Shares of Ra Pharmaceuticals Inc. (RARX) are up nearly 22% so far this month compared to the 8.5% gain of the iShares Nasdaq Biotechnology ETF (IBB) index during the same period.

M&As this week: Ligand Pharmaceuticals, CVS Health, Mundipharma

Ligand Pharmaceuticals has acquired Vernalis for $42.3m giving the former access to a portfolio of eight fully funded programmes, as...Read More... The post M&As this week: Ligand Pharmaceuticals, CVS Health, Mundipharma appeared first on Pharmaceutical Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks